Approval Briefs: Zohydro ER, Vyvanse For Binge Eating, Another Imbruvica Claim, Alcon Gains New Allergy Eye Drop
This article was originally published in The Pink Sheet Daily
Executive Summary
Reformulated opioid still doesn’t have abuse deterrence claim; Shire gains another indication for Vyvanse, this time in binge-eating; Imbruvica becomes the first drug approved for Waldenstrom’s macroglobulinemia; and, Alcon garners approval for once-daily eye drop.